Global Antibodies Market By Type (Monoclonal antibodies, Polyclonal antibodies, and Others), By Application (Hospitals, Long-term care facilities, and Others), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Antibodies Market By Type (Monoclonal antibodies, Polyclonal antibodies, and Others), By Application (Hospitals, Long-term care facilities, and Others), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)
Trusted Business Insights has published a comprehensive market research report on, Global Antibody Market By Product Type (Monoclonal Antibodies, Polyclonal Antibodies, Antibody-drug Complexes (ADCs)), By End-User (Hospitals, Long-term Care Facilities, Research Institutes), and by Region -Global Forecast to 2030, which offers a holistic view of the global antibody market through systematic segmentation that covers every aspect of the target market.

The global antibody market is projected to be US$ 156980.7 Mn in 2020 to reach US$ 354082.4 Mn by 2030 at a CAGR of 8.5%.

Antibodies also referred to as immunoglobulins, are secreted through B cells to neutralize antigens such as bacteria and viruses. Generally, all antibodies are of the same Y shaped the molecular structure of four polypeptides, with two heavy chains and two light chains. Each Y tip consists of a paratope (a structure analogous to a lock) that is specific for one particular epitope (similarly analogous to a key) on an antigen allowing these structure to bind together with precision. The ability of binding to an antigen has led to their abundant use in a variety of life sciences and medical science. These antibodies are classified into two types monoclonal and polyclonal, according to how they are created from lymphocytes. Each of them has important role in the immune system, treatments and diagnostics exam.

Both monoclonal and polyclonal antibodies have different advantages and disadvantages. Production time required for polyclonal antibodies is short; also they are low in cost. They are highly stable and tolerant of pH changes. Polyclonal antibodies have high affinity. Also, they are less sensitive to antigen changes as compared to monoclonal antibodies. Monoclonal antibodies have highly specific recognition of only one epitope of an antigen. They have high consistency among experiments. Monoclonal antibodies are excellent for affinity purification.

The antibody market is expected to grow in forecasted years and demand for these services is expected to remain steady in emerging economies owing to the favourable economic environment. Robust growth in the pharmaceuticals industry, particularly in developing economies is creating several opportunities in this market. Also, increased research activities in life sciences industries, coupled with growing proteomics and genomics research is further expected to propel market growth.

Antibodies hold diverse applications since these are widely used in autoimmune disorders, oncology, CNS disorders, neurobiology, cardiovascular disease, and other research areas, resulting in the stable growth of the market worldwide. Increase in research funding and increasing investments by pharmaceuticals and biotechnology companies is further supporting the growth of the market. Rapid growth in developing countries and increasing demand for personalized therapeutics are expected to offer significant growth opportunities for market players over the forecast period.


Global Antibody Market Revenue (US$ Mn), 2021 to 2030


Monoclonal antibodies segment accounts for more significant market share since these provide high specificity, selectivity and ease of production, as compared to other antibodies; and are thus a preferred choice in all types of research studies, which is providing opportunities for target market growth.

Robust growth in pharmaceuticals and biotechnology industries is a major factor driving the growth of the global antibody market.


Global Antibody Market by Formulation, 2018


On the basis of product type, the market is segmented into Monoclonal Antibodies, Polyclonal Antibodies and Antibody-drug Complexes (ADCs). Monoclonal Antibodies accounts for the majority share in the global antibody market.

On the basis of region, the market is segmented into North America, Europe, APAC, South America and MEA. North America accounts for the majority share in the global antibody market, followed by Europe. Emerging economies such as China and India are expected to register the highest growth rate over the forecast period. Countries and regions such as Japan, Southeast Asia and the rest of the world are expected to register stable growth over the forecast period.

The research report on the global antibody market includes profiles of some of the major companies such as Novartis AG, Roche Holding AG, Johnson & Johnson, Takeda Pharmaceutical Company, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc. etc.


Below are the active patents related to Antibodies Market.


Patent Number:- EP3101032A1

Anti-her2 antibody-drug conjugate

Abstract

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH- (CH2) n1-La-(CH2)n2-C(=O)- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the -(CH2)n2-C(=O)-moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Application File Date:- 2015-01-28

Application Date: 2015-01-28

Application Granted Date:- 2019-01-16

Current Assignee:- Daiichi Sankyo Co Ltd

Patent Number:- US20150368320A1

Polyclonal Antibodies Against Clostridium Difficile and Uses Thereof

Abstract

A polyclonal antibody composition prepared from eggs of immunized hens is used to treat C. difficile infections. Respective groups of hens are immunized with Toxin A or Toxin B of Clostridium difficile or a Clostridium difficile spore preparation. The polyclonal antibodies are recovered from eggs pooled from the immunized hens and the resulting powder is administered in a therapeutically effective amount to individuals infected with or suspected of being infected with C. difficile.

Application Date: 2015-06-22

Application Granted Date: 2018-01-23

Inventor: Pradip K. Maiti

Patent Number: EP2576609A1

Epitope tag for affinity-based applications

Abstract

The present invention relates to an epitope tag useful in affinity-based applications. The invention further includes fusion proteins, methods for preparing fusion proteins, nucleic acid molecules encoding these fusion proteins and recombinant host cells which contain these nucleic acid molecules. The invention also relates to nanobodies and other affinity ligands specifically recognizing said epitope tag, and uses thereof in affinity-based applications.

Application Date: 2011-05-25

Application Granted Date: 2018-11-14

Current Assignee: Vlaams Instituut voor Biotechnologie VIB , Vrije Universiteit Brussel VUB , Universite Libre de Bruxelles ULB

Key Market Segments

By Type

  
Monoclonal antibodies
  
Polyclonal antibodies
  
Antibody drug conjugates

BY Application

  
Hospitals
  
Long-term care facilities
  
Research institutes


Key Market Players included in the report:


  
AbbVie
  
Affinity Biologicals, Inc.
  
Agilent Technologies , Inc
  
Alexion Pharmaceuticals
  
Amgen
  
AstraZeneca
  
Bayer.
  
BD
  
Beckman Coulter, Inc.
  
Biogen
  
Bio-Rad Laboratories Inc.
  
Bristol-Myers Squibb
  
Cell Signaling Technology , Inc
  
F. Hoffmann-La Roche Ltd
  
GenScript.
  
GlaxoSmithKline
  
Johnson and Johnson
  
Lilly
  
Merck KGaAB
  
Novartis
  
Pfizer
  
QIAGEN
  
Roche
  
Sanofi
  
Seattle Genetics


Below are the key development related to Antibodies Market in 2020 and 2021.


June 2021: New and emerging biopharma companies working on early development can now leverage a better lab to clinic drug development solution designed to accelerate the journey from DNA to drug product. The enhanced Quick to Clinic solution from Thermo Fisher Scientific may help biopharma companies reach Phase I/First-In-Human trials and file for Investigational New Drug (IND) review in as little as 13 months from transfection. The new solution will be showcased this week at BIO Digital 2021. Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Program Call for Submissions to Support Research in Immuno-oncology. Source

June 2021: Thermo Fisher Scientific announced that submissions are now open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. This grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients. Source

June 2021: Thermo Fisher Scientific Launches Collection Kit to Streamline Saliva Testing. As businesses, universities and schools reopen, SARS-CoV-2 virus surveillance is critical to the management of outbreaks and emerging new strains, including the Delta variant that now makes up 91 percent of new cases in the United Kingdom. To support large-scale research and surveillance programs, Thermo Fisher Scientific introduced the Thermo Scientific SpeciMAX Saliva Collection Kit. Source